CHESTER, N.J., May 1 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. today announced that it plans to add approximately 25 new sales representatives to its sales force early in fiscal year 2007, which begins in July. The incremental sales force expansion will enable Adams to achieve a greater geographic reach and frequency of product details to healthcare professionals across the United States, as well as support the planned introduction of new products.
Commenting on the announcement, Robert D. Casale, executive vice president, chief marketing & development officer, said, “I believe our tremendous success for Mucinex(R) has resulted from our unique and synergistic marketing approach -- combining the right mix of consumer advertising and professional promotion.”
According to market research sponsored by Adams, Consumer Awareness of the Mucinex(R) brand has grown significantly as a result of the Company’s combined consumer and professional marketing efforts. In a recent survey, Total Brand Awareness of Mucinex(R) reached 60 percent for the four weeks ending April 15, 2006, compared to Total Brand Awareness of 36 percent, measured in early October 2005, at the beginning of the cough/cold season. Data from another company-sponsored study conducted last year (February 2005), indicate that 54 percent of Mucinex(R) users have received a recommendation from a healthcare professional.
John S. Thievon, executive vice president, commercial operations, noted, “Our existing 100-person sales force has contributed significantly to the overall marketing success of Mucinex(R). Going forward, it will be important for Adams to continue to strengthen its professional marketing efforts and sales force presence in anticipation of new product introductions.”
The new sales representatives are expected to be hired, trained and deployed by July 15, 2006. As needed, Adams will also increase its sales management, sales operations and training infrastructure to support the larger sales force.
About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
Forward-Looking Statements
This press release contains certain “forward-looking” statements, including the Company’s plans to increase the size of its sales force, the Company’s ability to broaden its geographic reach and frequency of product details, the Company’s ability to support the introduction of new products, and the Company’s need to strengthen marketing efforts and sales force presence. Such forward-looking statements can be identified by the words “plan,” “will,” “believe,” “expect,” and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the Company’s ability to: recruit and retain sales force personnel, capitalize on the increased size of the sales force, expand the number of products detailed by the sales force, and introduce new products; and other risk factors set forth under the headings “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Adams’ Rule 424(b)(4) Prospectus filed with the SEC on December 9, 2005 and under Item 1A. Risk Factors in Adams’ Quarterly Report on Form 10-Q for the period ended December 31, 2005. Except to the extent required by applicable securities laws, Adams is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements contained in this press release are made only as of the date of this presentation.
Adams Respiratory Therapeutics, Inc.
CONTACT: Janet M. Barth of Adams Respiratory Therapeutics, Inc.,+1-908-879-2428
Web site: http://www.adamsrt.com/
